GlaxoSmithKline has struck  a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells.
China’s Clover, which is based 600 miles west of the focal point of the COVID-19 outbreak, began work on a coronavirus vaccine late last month. Clover entered the race to develop a vaccine on the strength of earlier work to develop recombinant subunit-trimer vaccines for HIV and other enveloped RNA viruses. Animal data from those programs gave Clover confidence its platform for producing covalently-trimerized fusion proteins is applicable to COVID-19.
Now, GSK has lent its support to Clover’s efforts to test that hypothesis. GSK is providing its AS03 adjuvant technology to Clover, which plans to incorporate the mix of squalene, DL-α-tocopherol and polysorbate into its preclinical tests.
More at: //www.fiercebiotech.com/biotech/gsk-gives-clover-adjuvant-for-vaccine-against-indispensable-covid-19-protein?mkt_tok=eyJpIjoiWm1RMFl6ZzROR00wWkdOaiIsInQiOiJoMW53Y1VGbmIzaWphZDhwN2YzV2toQmFzb0RXeDl5Y3pZbGpRWEdhQXllK0NJU1wvaXlWYVk4Vk1Gcmk3ZWk0RXhZMDR1QmxjakVZYVAxQlAzS2c3c3NYNDZVSktOOGNrYWF2Z2ZSdnQ2d2luWmQydUZPVUlHTTNORDNrOE1jTkEifQ%3D%3D&mrkid=93736